DAFTAR PUSTAKA

(1)

61

Universitas Kristen Indonesia

1. Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset. CNS Neurol Disord - Drug Targets. 2017;16(5).

2. UNODC. What are NPS? [Internet]. 2022 [cited 2022 Jul 5]. Available from:

https://www.unodc.org/LSS/Page/NPS

3. Pusat Penelitian Data dan Informasi. Data Statistik Penangangan Kasus Narkotika [Internet]. 2022 [cited 2022 Jul 5]. Available from:

https://puslitdatin.bnn.go.id/portfolio/data-statistik-kasus-narkoba/

4. Quamila A, Savitri T. Cap Gorila, Ganja Sintetis yang Bikin Pemakainya Hidup Seperti Zombie [Internet]. 2021. Available from:

https://hellosehat.com/herbal-alternatif/herbal/efek-bahaya-cap-gorilla- ganja-sintetis/

5. Wiley JL, Marusich JA, Martin BR, Huffman JW. 1-Pentyl-3- phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend [Internet]. 2012;123(1–3):148–53. Available from: http://dx.doi.org/10.1016/j.drugalcdep.2011.11.001

6. Spaderna M, Addy PH, D’Souza DC. Spicing things up: Synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):525–40.

7. Brents LK, Prather PL. The K2/Spice Phenomenon: Emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014;46(1):72–

85.

8. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend [Internet]. 2014;144:12–41.

Available from: http://dx.doi.org/10.1016/j.drugalcdep.2014.08.005

9. Pusat Penelitian Data dan Informasi BNN. Survei Prevalensi 2018. Jakarta;

2019. 28–41 p.

10. Loeffler G, Delaney E, Hann M. International trends in spice use:

Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. Brain Res Bull

[Internet]. 2016;126:8–28. Available from:

http://dx.doi.org/10.1016/j.brainresbull.2016.04.013

11. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 27 p.

(2)

62

12. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 27–

28 p.

13. Arikunto S, Yuliana L. Manajemen Pendidikan. Yogyakarta: Aditya Media;

2008.

14. Alizamar, Cuoto N. Psikologi Persepsi & Desain Informasi; Sebuah Kajian Psikologi dan Prinsip Kognitif untuk kependidikan dan Desain Komunikasi Visual. Yogyakarta: Media Akademi; 2016. 15–16 p.

15. Walgito B. Penganta Psikologi Umum. 4th ed. Yogyakarta: Andi; 2004. 87–

88 p.

16. Walgito B. Penganta Psikologi Umum. 4th ed. Yogyakarta: Andi; 2004. 90 p.

17. Walgito B. Pengantar Psikologi Umum. 4th ed. Yogyakarta: Andi; 2004.

118–129 p.

18. Notoatmodjo S. Ilmu Perilaku Kesehatan. Jakarta: Rineka Cipta; 2018. 29 p.

30 p.

31 p.

21. UU Nomor 35 Tahun 2009. 2009;3.

22. Pusat Penelitian Data dan Informasi BNN. Survei Prevalensi 2018. Jakarta:

Pusat Penelitian Data dan Informasi Badan Narkotika Nasional Republik Indonesia; 2019. 8–11 p.

23. Pusat Penelitian Data dan Informasi BNN. Survei Prevalensi 2018. Jakarta;

2019. 18 p.

24. BNN. Indonesia Drugs Report 2021 [Internet]. Vol. 5, Paper Knowledge . Toward a Media History of Documents. Pusat Penelitian Data dan Informasi Badan Narkotika Nasional Republik Indonesia; 2021. 23–46 p. Available from: https://ppid.bnn.go.id/konten/unggahan/2020/10/IDR-2021.pdf 25. M. Castanento, D. Gorelick ND et al. Synthetic cannabinoids: Epidemiology,

pharmacodynamics, and clinical implications. Drug Alcohol Depend.

2014;144:12.

26. Spaderna M, Addy PH, D’Souza DC. Spicing things up: Synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):525.

(3)

63

27. Cooks T, Davis TK, Hu J, Metheny R, Schwartz M, Gerona R. “Smoking”

guns: Questions. Pediatr Nephrol. 2016;31(1):61–2.

28. Gottlieb S. Statement from FDA warning about significant health risks of contaminated illegal synthetic cannabinoid products that are being encountered by FDA [Internet]. 2018 [cited 2022 Jul 17]. Available from:

https://www.fda.gov/news-events/press-announcements/statement-fda- warning-about-significant-health-risks-contaminated-illegal-synthetic- cannabinoid#:~:text=The FDA has previously worked,imminent hazard to public safety.

29. De Luca MA, Castelli MP, Loi B, Porcu A, Martorelli M, Miliano C, et al.

Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids:

BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Neuropharmacology [Internet]. 2016;105(2016):630–8. Available from:

http://dx.doi.org/10.1016/j.neuropharm.2015.11.017

30. Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9- tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215.

31. Hruba L, McMahon LR. The cannabinoid agonist HU-210: Pseudo- irreversible discriminative stimulus effects in rhesus monkeys. Eur J Pharmacol [Internet]. 2014;727(1):35–42. Available from:

http://dx.doi.org/10.1016/j.ejphar.2014.01.041

32. De Luca MA, Bimpisidis Z, Melis M, Marti M, Caboni P, Valentini V, et al.

Stimulation of in vivo dopamine transmission and intravenous self- administration in rats and mice by JWH-018, a Spice cannabinoid.

Neuropharmacology [Internet]. 2015;99:705–14. Available from:

33. Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299–318.

34. Ossato A, Vigolo A, Trapella C, Seri C, Rimondo C, Serpelloni G, et al.

JWH-018 impairs sensorimotor functions in mice. Neuroscience [Internet].

2015;300:174–88. Available from:

http://dx.doi.org/10.1016/j.neuroscience.2015.05.021

35. Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al.

Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F- AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chem Neurosci.

2016;7(9):1241–54.

(4)

64

36. Irie T, Kikura-Hanajiri R, Usami M, Uchiyama N, Goda Y, Sekino Y. MAM- 2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptors.

Neuropharmacology [Internet]. 2015;95(March):479–91. Available from:

37. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012;40(11):2174–84.

38. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Toxicol Appl Pharmacol [Internet]. 2013;269(2):100–8. Available from:

http://dx.doi.org/10.1016/j.taap.2013.03.012

39. Chimalakonda K, James L, Radominska-Pandya A, Moran J. Sulfaphenazole and α-Naphthoflavone Attenuate the Metabolism of the Synthetic Cannabinoids JWH-018 and AM2201 Found in K2/Spice. Drug Metab Lett.

2014;7(1):34–8.

40. Bileck A, Ferk F, Al-Serori H, Koller VJ, Muqaku B, Haslberger A, et al.

Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage. Arch Toxicol. 2016;90(6):1369–82.

41. Carvalho AF, Reyes BAS, Ramalhosa F, Sousa N, Van Bockstaele EJ.

Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats. Brain Struct Funct. 2016;221(1):407–19.

42. Couceiro J, Bandarra S, Sultan H, Bell S, Constantino S, Quintas A.

Toxicological impact of JWH-018 and its phase I metabolite N-(3- hydroxypentyl) on human cell lines. Forensic Sci Int [Internet].

http://dx.doi.org/10.1016/j.forsciint.2016.03.024

43. Koller VJ, Ferk F, Al-Serori H, Mišík M, Nersesyan A, Auwärter V, et al.

Genotoxic properties of representatives of alkylindazoles and aminoalkyl- indoles which are consumed as synthetic cannabinoids. Food Chem Toxicol

[Internet]. 2015;80:130–6. Available from:

http://dx.doi.org/10.1016/j.fct.2015.03.004

44. Koller VJ, Zlabinger GJ, Auwärter V, Fuchs S, Knasmueller S.

Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1. Arch Toxicol.

(5)

65

2013;87(7):1287–97.

45. Lewis SEM, Paro R, Borriello L, Simon L, Robinson L, Dincer Z, et al.

Long-term use of HU210 adversely affects spermatogenesis in rats by modulating the endocannabinoid system. Int J Androl. 2012;35(5):731–40.

46. Grim TW, Wiebelhaus JM, Morales AJ, Negus SS, Lichtman AH. Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice. Drug Alcohol Depend [Internet].

http://dx.doi.org/10.1016/j.drugalcdep.2015.01.022

47. Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, et al. Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacol Res. 2015;102:22–32.

48. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid- terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–64.

49. Lafaye G, Karila L, Blecha L, Benyamina A. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017;19(3):309–16.

50. Maguire DR, France CP. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.

Eur J Pharmacol [Internet]. 2016;784:199–206. Available from:

http://dx.doi.org/10.1016/j.ejphar.2016.05.018

51. Botanas CJ, De La Peña JB, Dela Pena IJ, Tampus R, Kim HJ, Yoon SS, et al. Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist. Eur J Pharmacol [Internet]. 2015;766:135–41.

Available from: http://dx.doi.org/10.1016/j.ejphar.2015.10.004

52. Abdulrahim D, Bowden-Jones O. Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. Ne`Ptune [Internet]. 2015;335. Available from: http://neptune- clinical-guidance.co.uk/wp-content/uploads/2015/03/NEPTUNE-Guidance- March-2015.pdf

53. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE.

Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: Implications for drug abuse liability and pain therapys. J Pharmacol Exp Ther. 2013;346(3):350–61.

54. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to

(6)

66

Δ9-THC: Mechanism underlying greater toxicity? Life Sci [Internet].

2014;97(1):45–54. Available from:

http://dx.doi.org/10.1016/j.lfs.2013.09.017

55. Martinotti G, Santacroce R, Papanti D, Elgharably Y. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset.

CNS Neurol Disord - Drug Targets. 2017;16(5):20.

56. Santacroce R, Corazza O, Martinotti G, Bersani FS, Valeriani G, Giannantonio M Di. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Hum Psychopharmacol Clin Exp [Internet]. 20015;30:265–71. Available from:

http://dx.doi.org/10.1097/00019442-200303000-

00011%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=26 76262&tool=pmcentrez&rendertype=abstract%5Cnhttp://dx.doi.org/10.233 2/allergolint.O-07-525

57. Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol. 2016;30(12):1321–30.

58. Winstock AR, Barratt MJ. Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend [Internet]. 2013;131(1–3):106–11. Available from:

http://dx.doi.org/10.1016/j.drugalcdep.2012.12.011

59. Bilgrei OR. From “herbal highs” to the “heroin of cannabis”: Exploring the evolving discourse on synthetic cannabinoid use in a Norwegian Internet drug forum. Int J Drug Policy [Internet]. 2016;29:1–8. Available from:

http://dx.doi.org/10.1016/j.drugpo.2016.01.011

60. Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol. 2015;29(6):698–

703.

61. Zaurova M, Hoffman RS, Vlahov D, Manini AF. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose. J Med Toxicol [Internet]. 2016;12(4):335–40. Available from:

http://dx.doi.org/10.1007/s13181-016-0558-4

62. Katz KD, Leonetti AL, Bailey BC, Surmaitis RM, Eustice ER, Kacinko S, et al. Case series of synthetic cannabinoid intoxication from one toxicology center. West J Emerg Med. 2016;17(3):290–4.

63. Sherpa D, Paudel BM, Subedi BH, Chow RD. Synthetic cannabinoids: the

(7)

67

multi-organ failure and metabolic derangements associated with getting high. J Community Hosp Intern Med Perspect. 2015;5(4):27540.

64. Nurmedov S, Metin B, Ekmen S, Noyan O, Yilmaz O, Darcin A, et al.

Thalamic and cerebellar gray matter volume reduction in synthetic cannabinoids users. Eur Addict Res. 2015;21(6):315–20.

65. Spaderna M, Addy PH, D’Souza DC. Spicing things up: Synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):529.

66. Martinotti G, Santacroce R, Papanti D, Elgharably Y. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset.

CNS Neurol Disord - Drug Targets. 2017;16(5):5.

67. Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev. 2010;29(3):318–30.

68. Pusat Penelitian Data dan Informasi BNN. Indonesia Drugs Report 2021.

Jakarta: Pusat Penelitian Data dan Informasi Badan Narkotika Nasional Republik Indonesia; 2021. 10 p.

69. NIDA. Drugs, Brain, Behavior: The Science of Addiction. Sci Addict

[Internet]. 2020;7(3):1–32. Available from:

https://www.drugabuse.gov/publications/drugs-brains-behavior-science- addiction/drugs-brain

70. Kementrian Kesehatan. Riset Kesehatan Nasional [Internet]. Pusat Penelitian, Data, dan Informasi Badan Narkotika Nasional Republik

Indonesia; 2019. 62–64 p. Available from:

http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/L aporan_Nasional_RKD2018_FINAL.pdf

71. Nainggolan S. Pengantar Survei Riset Kesehatan Masyarakat. Cirebon: Nusa Literasi Inspirasi; 2018.

72. Sugiyono. METODE PENELITIAN KUANTITATIF, KUALITATIF, DAN R&D. Bandung: ALFABETA; 2013. 80–85 p.